GB201700557D0 - Novel peptides - Google Patents

Novel peptides

Info

Publication number
GB201700557D0
GB201700557D0 GBGB1700557.0A GB201700557A GB201700557D0 GB 201700557 D0 GB201700557 D0 GB 201700557D0 GB 201700557 A GB201700557 A GB 201700557A GB 201700557 D0 GB201700557 D0 GB 201700557D0
Authority
GB
United Kingdom
Prior art keywords
novel peptides
peptides
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1700557.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Revolo Biotherapeutics Ltd
Original Assignee
Peptinnovate Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptinnovate Ltd filed Critical Peptinnovate Ltd
Priority to GBGB1700557.0A priority Critical patent/GB201700557D0/en
Publication of GB201700557D0 publication Critical patent/GB201700557D0/en
Priority to US16/476,064 priority patent/US11098090B2/en
Priority to AU2018208077A priority patent/AU2018208077B2/en
Priority to ES18701789T priority patent/ES2970436T3/es
Priority to CA3049353A priority patent/CA3049353C/en
Priority to JP2019538337A priority patent/JP7252895B2/ja
Priority to EP18701789.2A priority patent/EP3568148B1/en
Priority to CN201880017906.0A priority patent/CN110381979A/zh
Priority to PCT/GB2018/050072 priority patent/WO2018130834A1/en
Priority to JP2022188982A priority patent/JP2023029902A/ja
Priority to JP2024196183A priority patent/JP2025032107A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
GBGB1700557.0A 2017-01-12 2017-01-12 Novel peptides Ceased GB201700557D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GBGB1700557.0A GB201700557D0 (en) 2017-01-12 2017-01-12 Novel peptides
PCT/GB2018/050072 WO2018130834A1 (en) 2017-01-12 2018-01-11 Mycobacteria tuberculosis chaperonin 60.1 peptides and uses thereof
CA3049353A CA3049353C (en) 2017-01-12 2018-01-11 Chaperonin 60.1 Peptides of Mycobacterium Tuberculosis and Their Uses
AU2018208077A AU2018208077B2 (en) 2017-01-12 2018-01-11 Mycobacteria tuberculosis chaperonin 60.1 peptides and uses thereof
ES18701789T ES2970436T3 (es) 2017-01-12 2018-01-11 Péptidos de chaperonina 60.1 de tuberculosis micobacteriana y usos de los mismos
US16/476,064 US11098090B2 (en) 2017-01-12 2018-01-11 Mycobacteria tuberculosis chaperonin 60.1 peptides and uses thereof
JP2019538337A JP7252895B2 (ja) 2017-01-12 2018-01-11 結核菌シャペロニン６０．１ペプチドおよびその使用
EP18701789.2A EP3568148B1 (en) 2017-01-12 2018-01-11 Mycobacteria tuberculosis chaperonin 60.1 peptides and uses thereof
CN201880017906.0A CN110381979A (zh) 2017-01-12 2018-01-11 结核分枝杆菌陪伴蛋白60.1肽及其用途
JP2022188982A JP2023029902A (ja) 2017-01-12 2022-11-28 結核菌シャペロニン６０．１ペプチドおよびその使用
JP2024196183A JP2025032107A (ja) 2017-01-12 2024-11-08 結核菌シャペロニン６０．１ペプチドおよびその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1700557.0A GB201700557D0 (en) 2017-01-12 2017-01-12 Novel peptides

Publications (1)

Publication Number Publication Date
GB201700557D0 true GB201700557D0 (en) 2017-03-01

Family

ID=58463310

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1700557.0A Ceased GB201700557D0 (en) 2017-01-12 2017-01-12 Novel peptides

Country Status (9)

Country Link
US (1) US11098090B2 (enExample)
EP (1) EP3568148B1 (enExample)
JP (3) JP7252895B2 (enExample)
CN (1) CN110381979A (enExample)
AU (1) AU2018208077B2 (enExample)
CA (1) CA3049353C (enExample)
ES (1) ES2970436T3 (enExample)
GB (1) GB201700557D0 (enExample)
WO (1) WO2018130834A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12331088B2 (en) 2017-01-12 2025-06-17 Revolo Biotherapeutics Limited Method for the treatment of a relapsing-remitting condition
GB201700555D0 (en) * 2017-01-12 2017-03-01 Peptinnovate Ltd Method for the treatment of a relapsing-remitting condition
US12358957B2 (en) 2017-01-12 2025-07-15 Revolo Biotherapeutics Limited Method for the acute treatment of atopic dermatitis and allergic skin hypersensitivity
GB201700557D0 (en) * 2017-01-12 2017-03-01 Peptinnovate Ltd Novel peptides
WO2023223015A1 (en) 2022-05-16 2023-11-23 Revolo Biotherapeutics Limited Methods and compositions for preventing or treating food allergies
US20240287781A1 (en) 2023-02-28 2024-08-29 Toto Ltd. Wall-mounted flush toilet
WO2024218571A1 (en) * 2023-04-18 2024-10-24 Revolo Biotherapeutics Limited Methods and compositions for preventing or treating eosinophilic esophagitis
WO2025037259A1 (en) 2023-08-15 2025-02-20 Revolo Biotherapeutics Limited Methods and compositions for preventing or treating severe asthma
WO2025255468A2 (en) 2024-06-06 2025-12-11 Miguel Guzman Subcutaneous formulation of a peptide derived from chaperonin 60.1

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0028122D0 (en) 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
FR2858936A1 (fr) 2003-08-22 2005-02-25 Diatos Potentialisation de l'activation de prodrogues de haut poids moleculaire
WO2008033820A2 (en) 2006-09-11 2008-03-20 The Board Of Trustees Of The University Of Illinois Modifications of cupredoxin derived peptides and methods of use thereof
GB0803369D0 (en) * 2008-02-25 2008-04-02 Helperby Therapeutics Ltd Biological materials and uses thereof
CA2779730C (en) 2009-11-05 2019-04-30 University Of Virginia Patent Foundation Compositions and methods for detecting plectin-1 as a biomarker for cancer
GB201118201D0 (en) 2011-10-21 2011-12-07 Helperby Therapeutics Ltd Novel peptides
GB201700557D0 (en) * 2017-01-12 2017-03-01 Peptinnovate Ltd Novel peptides

Also Published As

Publication number Publication date
US11098090B2 (en) 2021-08-24
AU2018208077A1 (en) 2019-07-25
EP3568148A1 (en) 2019-11-20
AU2018208077B2 (en) 2021-11-11
CA3049353A1 (en) 2018-07-19
WO2018130834A1 (en) 2018-07-19
ES2970436T3 (es) 2024-05-28
JP2020504161A (ja) 2020-02-06
JP2025032107A (ja) 2025-03-11
EP3568148B1 (en) 2023-11-01
US20200071365A1 (en) 2020-03-05
JP7252895B2 (ja) 2023-04-05
JP2023029902A (ja) 2023-03-07
EP3568148C0 (en) 2023-11-01
CN110381979A (zh) 2019-10-25
CA3049353C (en) 2024-10-29

Similar Documents

Publication Publication Date Title
IL275298A (en) Mitochondria-targeted peptides
GB201719557D0 (en) Polypeptide
GB201508337D0 (en) Novel peptides
SG10202109234YA (en) Novel peptide
GB201700557D0 (en) Novel peptides
SG11202005653RA (en) Novel peptide
GB201607534D0 (en) Peptides
GB201520539D0 (en) Peptides
GB201604468D0 (en) Peptides
GB201520543D0 (en) Peptides
GB201520536D0 (en) Peptides
GB201520546D0 (en) Peptides
GB201520545D0 (en) Peptides
GB201506316D0 (en) Novel peptide
GB201520541D0 (en) Peptides
GB201520550D0 (en) Peptides
GB201520544D0 (en) Peptides
GB201607535D0 (en) Peptides
GB201520542D0 (en) Peptides
GB201520548D0 (en) Peptides
GB201719520D0 (en) Neuroprotectvie peptide
GB201715378D0 (en) Peptides
GB201715379D0 (en) Peptides
GB201711620D0 (en) Peptides
GB201707837D0 (en) Peptides

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)